Company

BRL MedicineCAR-T

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

The CD19‑targeted genetically modified allogeneic chimeric antigen receptor T‑cell (CAR‑T) injection of Shanghai BRL Medicine, Inc. has been included in the Center for Drug Evaluation (CDE) of China's National Medical…

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611
ADC / XDCIPO

Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611

Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials
CancerHengrui Pharmaceuticals

Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials

Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21
Genhouse BioIPO

Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21

CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio
AstraZenecaAZ

CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio

Show More